Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) issued an announcement. The company announced three pre-clinical research results at the 2024 American Association for Cancer Research (AACR) annual meeting, involving the company's original Class 1 drug olevatinib (trade name: Nellick)), MDM2-p53 inhibitor APG-115, FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and embryonic ectodermal development protein (EED) inhibitor APG-5918 are important varieties.
The results of the three preclinical studies are as follows:
Orebatinib, a novel multi-target tyrosine kinase inhibitor, shows excellent anti-tumor effects in SDH deficient tumors
Embryonic ectodermal development (EED) inhibitor APG-5918 (eEdi-5273) combined with MDM2 inhibitor alrizomadlin (APG-115) co-inhibits tumor growth in a preclinical model of prostate cancer (PCa)
The novel focal adhesion kinase (FAK) inhibitor APG-2449 inhibits tumor cell metastasis and enhances the antitumor effect of the polyethylene glycol liposome doxorubicin (PLD) in epithelial ovarian cancer (EOC)